The MarketWatch News Department was not involved in the creation of this content. -- Results of a Phase 2a dose escalating study of lingdolinurad (ABP-671) for chronic gout, which enrolled patients ...

Please provide your email address to receive an email when new articles are posted on . “Therefore, it is very important for patients and clinicians alike to be aware of the cardiovascular safety of ...

Colchicine, a cheap and widely used gout drug, may help prevent heart attacks and strokes in people with cardiovascular disease. Trials involving nearly 23,000 patients show meaningful reductions in ...

Obesity in Men Hampers Response to Gout Treatment Obesity significantly reduced the effectiveness of febuxostat-based urate-lowering therapy among men with gout, a recent study reveals. Medscape ...

The drug colchicine may reduce cardiovascular outcomes among patients with gout, based on a range of retrospective data that suggest improved outcomes and mechanistic connections between gout and ...

Gout is the most common form of inflammatory arthritis, with a worldwide prevalence of approximately 4%. The accumulation of monosodium urate crystals in gout leads to the clinical manifestations of ...

In recent years, scientists have increasingly turned their attention to older, affordable drugs to explore whether they offer benefits beyond their original purpose. Colchicine, a cheap and widely ...

Results of a Phase 2a dose escalating study of lingdolinurad (ABP-671) for chronic gout, which enrolled patients with mild to moderate renal impairment, showed the URAT1 inhibitor lowered serum uric ...